Neurofibromatosis type 1 (NF1)
Research & Innovation
At Children’s Hospital Boston, we’re known for our science-driven approach and our intense culture of innovation—a philosophy that lets us push the boundaries of pediatric care.
We’re one of nine sites selected country-wide for expertise in taking care of patients with neurofibromatosis to participate in the Department of Defense-funded Clinical Trials Consortium. As part of the Consortium, we run trials aimed at finding new ways to treat:
- progressive plexiform neurofibromas
- pediatric brain tumors
- pediatric learning disabilities
- malignant peripheral nerve sheath tumors
We also lead and participate in clinical studies that investigate:
- growth abnormalities in children with NF1, including premature puberty
- bone density in neurofibromatosis
- the relationship between a mutation and the symptoms that people with that mutation may or may not develop
- early ways to detect complications of NF1
- how new blood vessels are created in tumors associated with NF1
If you’d like to find out more about our clinical trials or see whether your child might be a candidate, please talk to your child’s doctor or email us at firstname.lastname@example.org.